With over 25 years in the global biopharmaceutical industry, Dr. Andreas Woppmann, Senior Consultant with BPTC’s advanceONE™ Division, is a proven product development and operations leader and executive with comprehensive strategic and operational experience ranging from the start-up stage to globally operating, public companies with a diverse commercial product portfolio.
Throughout his career, Dr. Woppmann has been a key contributor to the successful development, licensure and commercialization of more than a dozen novel medicines from rationally designed small molecules, oligonucleotides and oligopeptides to monoclonal antibodies, complex glycoproteins and innovative vaccines.
Before joining BioProcess Technology Consultants, Dr. Woppmann served as Vice President of Manufacturing Operations at Ariad Pharmaceuticals, where he was responsible for pharmaceutical development, manufacturing operations, quality control, CMC, and supply chain functions. Prior to Ariad, he served as Vice President of Pharmaceutical Development, Operations and Quality at Endo Pharmaceuticals (formerly Indevus), as well as Senior Director of Analytical and Quality at Agenus (formerly Antigenics), and as Section Head at Biogen Idec, where he was responsible for analytical development, quality control and cross-functional CMC leadership. He has led the design and implementation of effective pharmaceutical operations and organizational structures that efficiently combine internal competencies with external capacities and cohesive quality management systems.
Prior to joining the US biopharmaceutical industry, Dr. Woppmann spent six years as a scientist at the Max-Planck Institute for Molecular Genetics in Germany, where he obtained his doctorate with emphasis on molecular biology and biochemistry. Dr. Woppmann has been an invited speaker at conferences in the U.S. and Europe, and has authored numerous, peer-reviewed publications.